Compare
Regeneron Pharmaceuticals, Inc. vs Organon & Co. vs Abbott Laboratories vs Bristol Myers Squibb Co
| Latest fiscal year | Regeneron Pharmaceuticals, Inc. REGN | Organon & Co. OGN | Abbott Laboratories ABT | Bristol Myers Squibb Co BMY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $14.34B | $6.22B | $44.33B | $48.19B |
| Revenue growth (YoY) | +1.0% | -2.9% | +5.7% | -0.2% |
| Gross margin | n/a | 53.3% | 56.4% (computed) | n/a |
| Operating margin | 24.9% | n/a | 18.2% | n/a |
| Net margin | 31.4% | 3.0% | 14.7% | 14.6% |
| Net income | $4.50B | $187.00M | $6.52B | $7.05B |
| EPS (Diluted) | $41.48 | $0.72 | $3.72 | $3.46 |
| Operating cash flow | $4.98B | $700.00M | $9.57B | $14.16B |
| Free cash flow | $4.08B | $538.00M | $7.39B | $12.85B |
| Cash & equivalents | $3.12B | $574.00M | $8.52B | $10.21B |
| Total assets | $40.56B | $12.87B | $86.71B | $90.04B |
| Total liabilities | $9.30B | $12.12B | n/a | $71.53B |
| Shareholders' equity | $31.26B | $752.00M | $52.13B | $18.47B |
| Return on year-end equity | 14.4% | 24.9% | 12.5% | 38.2% |
| Shares outstanding | n/a | 260.32M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Regeneron Pharmaceuticals, Inc. | Organon & Co. | Abbott Laboratories | Bristol Myers Squibb Co |
|---|---|---|---|---|
| Latest | $14.34B Ended 2025-12-31 | $6.22B Ended 2025-12-31 | $44.33B Ended 2025-12-31 | $48.19B Ended 2025-12-31 |
| 1 year earlier | $14.20B Ended 2024-12-31 | $6.40B Ended 2024-12-31 | $41.95B Ended 2024-12-31 | $48.30B Ended 2024-12-31 |
| 2 years earlier | $13.12B Ended 2023-12-31 | $6.26B Ended 2023-12-31 | $40.11B Ended 2023-12-31 | $45.01B Ended 2023-12-31 |
| 3 years earlier | $12.17B Ended 2022-12-31 | $6.17B Ended 2022-12-31 | $43.65B Ended 2022-12-31 | $46.16B Ended 2022-12-31 |
| 4 years earlier | $16.07B Ended 2021-12-31 | $6.30B Ended 2021-12-31 | $43.08B Ended 2021-12-31 | $46.38B Ended 2021-12-31 |